Retention, inactive disease, LDA and response rates after 6 and 12 months of secukinumab treatment stratified across European registries (ICEBIO (Iceland) is excluded from the table due to <10 patients at secukinumab initiation)
| Months | ARTIS | RRBR | SCQM | ATTRA | DANBIO | BIOBADASER | TURKBIO | NOR-DMARD | biorx.si | Reuma.pt | GISEA | ROB-FIN | P value* | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Retention rate, % (95% CI) | 6 | 78% (74–82%) | 89% (86–93%) | 77% (71–83%) | 88% (84–93%) | 73% (67–81%) | 82% (75–89%) | 82% (75–91%) | 76% (66–87%) | 87% (80–96%) | 93% (86–100%) | 89% (80–99%) | 70% (57–85%) | <0.001 |
| 12 | 64% (59–69%) | 85% (81–90%) | 64% (58–71%) | 84% (79–90%) | 64% (56–73%) | 75% (67–83%) | <10 patients | 56% (43–71%) | 83% (74–93%) | 86% (77–96%) | 86% (77–97%) | 53% (40–71%) | <0.001 | |
| BASDAI<2, % | 6 | 10% | 56% | 17% | 35% | 11% | 0% | 42% | 12% | 25% | 11% | 9% | 25% | <0.001 |
| 12 | 9% | 71% | 9% | 44% | 15% | 20% | <10 patients | 7% | 17% | 21% | 19% | 33% | <0.001 | |
| BASDAI<4, % | 6 | 31% | 89% | 34% | 67% | 26% | 38% | 64% | 45% | 54% | 36% | 46% | 43% | <0.001 |
| 12 | 31% | 96% | 35% | 73% | 36% | 47% | <10 patients | 33% | 46% | 59% | 63% | 62% | <0.001 | |
| ASDAS<1.3, % | 6 | 7% | 13% | 8% | 9% | 4% | <10 patients | 18% | 7% | 0% | 5% | 13% | 8% | 0.09 |
| 12 | 5% | 15% | 8% | 20% | 12% | 14% | <10 patients | 0% | 0% | 8% | 23% | 10% | 0.11 | |
| ASDAS<2.1, % | 6 | 15% | 35% | 18% | 32% | 16% | <10 patients | 25% | 27% | 27% | 11% | 35% | 25% | <0.001 |
| 12 | 18% | 52% | 19% | 31% | 19% | 57% | <10 patients | 7% | 10% | 27% | 23% | 20% | <0.001 | |
| BASDAI50 response, % | 6 | 34% | 86% | 29% | 68% | 28% | 33% | 52% | 36% | 57% | 53% | 28% | 32% | <0.001 |
| 12 | 21% | 92% | 24% | 68% | 29% | 50% | <10 patients | 13% | 72% | 53% | 31% | 37% | <0.001 | |
| ASAS20 response, % | 6 | 31% | – | 30% | 63% | 27% | – | 46% | – | <10 patients | – | – | <10 patients | <0.001 |
| 12 | 18% | – | 31% | 74% | 36% | – | <10 patients | – | <10 patients | – | – | <10 patients | <0.001 | |
| ASAS40 response, % | 6 | 18% | – | 24% | 52% | 12% | – | 29% | – | <10 patients | – | – | <10 patients | <0.001 |
| 12 | 7% | – | 15% | 55% | 21% | – | <10 patients | – | <10 patients | – | – | <10 patients | <0.001 |
*Comparisons across the registries were performed with Kaplan-Meier with log-rank test for retention rates and χ² test for disease states and response rates. –, not collected; ASAS20/40, Assessment of Spondyloarthritis International Society 20/40 response; ASDAS, Ankylosing Spondylitis Disease Activity Score; ASDAS-CII, ASDAS clinically important improvement (≥1.1); ASDAS-MI, ASDAS major improvement (≥2.0); ASAS20/40, Assessment of Spondyloarthritis International Society 20/40 response; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASDAI50, 50% improvement in BASDAI; BASFI, Bath Ankylosing Spondylitis Functional Index. Number of available cases for each of the analyses are shown in online supplemental table 2.